Literature DB >> 24500820

Morphometric age and mortality after liver transplant.

Seth A Waits1, Edward K Kim1, Michael N Terjimanian1, Lindsay M Tishberg2, Calista M Harbaugh1, Kyle H Sheetz1, Christopher J Sonnenday1, June Sullivan1, Stewart C Wang1, Michael J Englesbe1.   

Abstract

IMPORTANCE: Morphometric assessment has emerged as a strong predictor of postoperative morbidity and mortality. However, a gap exists in translating this knowledge to bedside decision making. We introduced a novel measure of patient-centered surgical risk assessment: morphometric age.
OBJECTIVE: To investigate the relationship between morphometric age and posttransplant survival. DATA SOURCES: Medical records of recipients of deceased-donor liver transplants (study population) and kidney donors/trauma patients (morphometric age control population). STUDY SELECTION: A retrospective cohort study of 348 liver transplant patients and 3313 control patients. We assessed medical records for validated morphometric characteristics of aging (psoas area, psoas density, and abdominal aortic calcification). We created a model (stratified by sex) for a morphometric age equation, which we then calculated for the control population using multivariate linear regression modeling (covariates). These models were then applied to the study population to determine each patient's morphometric age. DATA EXTRACTION AND SYNTHESIS: All analytic steps related to measuring morphometric characteristics were obtained via custom algorithms programmed into commercially available software. An independent observer confirmed all algorithm outputs. Trained assistants performed medical record review to obtain patient characteristics.
RESULTS: Cox proportional hazards regression model showed that morphometric age was a significant independent predictor of overall mortality (hazard ratio, 1.03 per morphometric year [95% CI, 1.02-1.04; P < .001]) after liver transplant. Chronologic age was not a significant covariate for survival (hazard ratio, 1.02 per year [95% CI, 0.99-1.04; P = .21]). Morphometric age stratified patients at high and low risk for mortality. For example, patients in the middle chronologic age tertile who jumped to the oldest morphometric tertile have worse outcomes than those who jumped to the youngest morphometric tertile (74.4% vs 93.2% survival at 1 year [P = .03]; 45.2% vs 75.0% at 5 years [P = .03]). CONCLUSIONS AND RELEVANCE: Morphometric age correlated with mortality after liver transplant with better discrimination than chronologic age. Assigning a morphometric age to potential liver transplant recipients could improve prediction of postoperative mortality risk.

Entities:  

Mesh:

Year:  2014        PMID: 24500820     DOI: 10.1001/jamasurg.2013.4823

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  22 in total

1.  Frailty, mycophenolate reduction, and graft loss in kidney transplant recipients.

Authors:  Mara A McAdams-DeMarco; Andrew Law; Jingwen Tan; Cassandra Delp; Elizabeth A King; Babak Orandi; Megan Salter; Nada Alachkar; Niraj Desai; Morgan Grams; Jeremy Walston; Dorry L Segev
Journal:  Transplantation       Date:  2015-04       Impact factor: 4.939

Review 2.  5th International ACC Symposium: Surgical Considerations in the Treatment of Adrenocortical Carcinoma: 5th International ACC Symposium Session: Who, When and What Combination?

Authors:  Barbra S Miller
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

3.  One-year postoperative resource utilization in sarcopenic patients.

Authors:  Peter S Kirk; Jeffrey F Friedman; David C Cron; Michael N Terjimanian; Stewart C Wang; Darrell A Campbell; Michael J Englesbe; Nicole L Werner
Journal:  J Surg Res       Date:  2015-04-30       Impact factor: 2.192

4.  Abdominal lean muscle is associated with lower mortality among kidney waitlist candidates.

Authors:  Jayme E Locke; J Jeffrey Carr; Sangeeta Nair; James G Terry; Rhiannon D Reed; Grant D Smith; Dorry L Segev; Vineeta Kumar; Cora E Lewis
Journal:  Clin Transplant       Date:  2017-02-08       Impact factor: 2.863

5.  Dorsal muscle group area and surgical outcomes in liver transplantation.

Authors:  Christopher S Lee; David C Cron; Michael N Terjimanian; Leah D Canvasser; Alyssa A Mazurek; Ellen Vonfoerster; Lindsay M Tishberg; Patrick W Underwood; Eric T Chang; Stewart C Wang; Christopher J Sonnenday; Michael J Englesbe
Journal:  Clin Transplant       Date:  2014-08-11       Impact factor: 2.863

6.  Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools.

Authors:  Danny Lascano; Jamie S Pak; Max Kates; Julia B Finkelstein; Mark Silva; Elizabeth Hagen; Arindam RoyChoudhury; Trinity J Bivalacqua; G Joel DeCastro; Mitchell C Benson; James M McKiernan
Journal:  Urol Oncol       Date:  2015-07-09       Impact factor: 3.498

Review 7.  An overview of frailty in kidney transplantation: measurement, management and future considerations.

Authors:  Meera N Harhay; Maya K Rao; Kenneth J Woodside; Kirsten L Johansen; Krista L Lentine; Stefan G Tullius; Ronald F Parsons; Tarek Alhamad; Joseph Berger; XingXing S Cheng; Jaqueline Lappin; Raymond Lynch; Sandesh Parajuli; Jane C Tan; Dorry L Segev; Bruce Kaplan; Jon Kobashigawa; Darshana M Dadhania; Mara A McAdams-DeMarco
Journal:  Nephrol Dial Transplant       Date:  2020-07-01       Impact factor: 5.992

Review 8.  Role of frailty and sarcopenia in predicting outcomes among patients undergoing gastrointestinal surgery.

Authors:  Doris Wagner; Mara McAdams DeMarco; Neda Amini; Stefan Buttner; Dorry Segev; Faiz Gani; Timothy M Pawlik
Journal:  World J Gastrointest Surg       Date:  2016-01-27

9.  Frailty Is Associated With Increased Rates of Acute Cellular Rejection Within 3 Months After Liver Transplantation.

Authors:  Laila Fozouni; Yara Mohamad; Adrienne Lebsack; Chris Freise; Peter Stock; Jennifer C Lai
Journal:  Liver Transpl       Date:  2020-02-03       Impact factor: 5.799

10.  Sarcopenia in Liver Transplantation.

Authors:  John Montgomery; Michael Englesbe
Journal:  Curr Transplant Rep       Date:  2019-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.